Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Laekna Limited
Laekna Limited
National Institutes of Health Clinical Center (CC)
Arcus Biosciences, Inc.
Washington University School of Medicine
Merck Sharp & Dohme LLC
Novita Pharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc
Revolution Medicines, Inc.
Arbeitsgemeinschaft medikamentoese Tumortherapie
Labcorp Corporation of America Holdings, Inc
Immatics US, Inc.
Zymeworks BC Inc.
Stanford University
Symphogen A/S
DxTerity Diagnostics
Cancer Research and Biostatistics Clinical Trials Consortium
Celldex Therapeutics
Umeå University
Duke University
Prelude Therapeutics
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
Incyte Corporation
Exact Sciences Corporation
Boryung Pharmaceutical Co., Ltd
MacroGenics
Weill Medical College of Cornell University
Seagen Inc.
Incyte Corporation
Seagen Inc.
Gilead Sciences
Mie University
Seagen Inc.
Incyte Corporation
Ciusss de L'Est de l'Île de Montréal
Abramson Cancer Center at Penn Medicine
Eli Lilly and Company
Swiss Cancer Institute
Inovio Pharmaceuticals
Memorial Sloan Kettering Cancer Center
Shandong Cancer Hospital and Institute
Royal Marsden NHS Foundation Trust
University of Kansas Medical Center
Roswell Park Cancer Institute
Ohio State University Comprehensive Cancer Center
Amgen
Santa Maria Biotherapeutics
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center